Ontology highlight
ABSTRACT:
SUBMITTER: Cleary JM
PROVIDER: S-EPMC6763367 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
Cleary James M JM Horick Nora K NK McCleary Nadine Jackson NJ Abrams Thomas A TA Yurgelun Matthew B MB Azzoli Christopher G CG Rubinson Douglas A DA Brooks Gabriel A GA Chan Jennifer A JA Blaszkowsky Lawrence S LS Clark Jeffrey W JW Goyal Lipika L Meyerhardt Jeffrey A JA Ng Kimmie K Schrag Deborah D Savarese Diane M F DMF Graham Christopher C Fitzpatrick Bridget B Gibb Kathryn A KA Boucher Yves Y Duda Dan G DG Jain Rakesh K RK Fuchs Charles S CS Enzinger Peter C PC
Cancer 20190326 13
<h4>Background</h4>Antiangiogenic therapy is a proven therapeutic modality for refractory gastric and gastroesophageal junction adenocarcinoma. This trial assessed whether the addition of a high affinity angiogenesis inhibitor, ziv-aflibercept, could improve the efficacy of first-line mFOLFOX6 (oxaliplatin, leucovorin, and bolus plus infusional 5- fluorouracil) in metastatic esophagogastric adenocarcinoma.<h4>Methods</h4>Patients with treatment-naive metastatic esophagogastric adenocarcinoma wer ...[more]